This article is more than 5 years old. Information may no longer be current.
LExICon
Lead Extraction in Contemporary Settings
Trial examined safety, efficacy, indications and outcomes of laser-assisted percutaneous lead extraction in a large sample of consecutive patients.
Design: observational, retrospective
Patients: 1,449
Centers: 13
Countries: United States, Canada
RESULTS: There were 63 major adverse events in 58 patients (4.0%) and 27 minor adverse events in 26 patients (1.8%). Results from a multivariate model indicated that only patients with BMI <25 were more likely to experience a major adverse event related to the extraction procedure (P=.0132). A separate multivariate model suggested that patients with creatinine =2 mg/dL; diabetes; BMI <25; and infection were all at increased risk for death (P<.0001). The overall in-hospital all-cause mortality rate was 1.86% but was 4.3% when associated with devicerelated endocarditis; 7.9% when associated with endocarditis and diabetes; and 12.4% when associated with creatinine >2 mg/dL and endocarditis.
Published in: J Am Coll Cardiol. 2010;55:579-586.
Click here to read more about the LExICon trial.